Fox Chase Clinical Trial Tests First of Its Kind Antibody: MM-111 Antibody Uses HER2 Target to Reach and Block HER3
CHICAGO, IL (June 7, 2010) – Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.